A retrospective study to evaluate whether positivity of rheumatoid factor and anti-cyclic citrullinated peptide associated with response rate of infliximab, tocilizumab and abatacept in patients with rheumatoid arthritis.

Trial Profile

A retrospective study to evaluate whether positivity of rheumatoid factor and anti-cyclic citrullinated peptide associated with response rate of infliximab, tocilizumab and abatacept in patients with rheumatoid arthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2015

At a glance

  • Drugs Abatacept (Primary) ; Infliximab (Primary) ; Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top